

Chronic kidney disease as cause of cardiovascular morb

Nephrology Dialysis Transplantation

20, 1048-1056

DOI: [10.1093/ndt/gfh813](https://doi.org/10.1093/ndt/gfh813)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Screening techniques for detecting chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2005, 14, 567-572.	1.0	22
3	Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidase-dependent superoxide production in patients with early chronic kidney disease. <i>Kidney International</i> , 2005, 68, S71-S75.	2.6	45
4	Challenging times in renal medicine: an opportunity for clinical biochemistry. <i>Annals of Clinical Biochemistry</i> , 2005, 42, 318-320.	0.8	2
5	Estimating kidney function in adults using formulae. <i>Annals of Clinical Biochemistry</i> , 2005, 42, 321-345.	0.8	206
7	New insights on inflammation in chronic kidney disease—genetic and non-genetic factors. <i>Nephrologie Et Therapeutique</i> , 2006, 2, 111-119.	0.2	58
8	Is Peritoneal Dialysis Associated with Increased Cardiovascular Morbidity and Mortality?. <i>Peritoneal Dialysis International</i> , 2006, 26, 429-434.	1.1	17
10	Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2133-2143.	0.4	132
11	THE EPIDEMIC OF CARDIO-VASCULAR DISEASE IN RENAL FAILURE: WHERE DOES IT COME FROM, WHERE DO WE GO?. <i>Acta Clinica Belgica</i> , 2006, 61, 205-211.	0.5	5
12	Clinical assessment of endothelial dysfunction: combine and rule. <i>Current Opinion in Nephrology and Hypertension</i> , 2006, 15, 617-624.	1.0	23
14	Anemia and cardiovascular and kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2006, 15, 117-122.	1.0	6
15	Inflammation in end-stage renal disease: The hidden enemy (Review Article). <i>Nephrology</i> , 2006, 11, 36-41.	0.7	157
16	Elevation of circulating endothelial microparticles in patients with chronic renal failure. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 566-573.	1.9	287
17	Online Hemodiafiltration. <i>Artificial Organs</i> , 2006, 30, 579-585.	1.0	18
18	Protecting the endothelium: A new focus for management of chronic kidney disease. <i>Hemodialysis International</i> , 2006, 10, 42-48.	0.4	24
19	Increased Mortality in Chronic Kidney Disease: A Call to Action. <i>American Journal of the Medical Sciences</i> , 2006, 331, 150-153.	0.4	44
20	CHRONIC KIDNEY DISEASE: THE CINDERELLA OF GENERAL MEDICINE. <i>Acta Clinica Belgica</i> , 2006, 61, 319-325.	0.5	2
21	Being an Inflamed Peritoneal Dialysis Patient – A Dante’s Journey. , 2006, 150, 144-151.		19
22	The importance of standardization of creatinine in the implementation of guidelines and recommendations for CKD: implications for CKD management programmes. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 77-83.	0.4	93

#	ARTICLE	IF	CITATIONS
23	Renal transplant dysfunctionâ€™ importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2282-2289.	0.4	50
24	Oxidative stress and atherosclerosis in early chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2686-2690.	0.4	68
25	Beyond phosphateâ€“role of uraemic toxins in cardiovascular calcification. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3354-3357.	0.4	9
26	Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2006, 22, 53-58.	0.4	31
27	Chronic kidney disease: evolving strategies for detection and management of impaired renal function. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2006, 99, 365-375.	0.2	28
28	The Chronic Kidney Disease Epidemic: Stepping Back and Looking Forward. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 2967-2973.	3.0	57
29	Clinical Practice Guidelines in nephrologyâ€™ for worse or for better. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1145-1153.	0.4	25
30	Macroalbuminuria Is a Better Risk Marker than Low Estimated GFR to Identify Individuals at Risk for Accelerated CFR Loss in Population Screening. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 2582-2590.	3.0	176
31	N-3 Fatty Acids as Secondary Prevention against Cardiovascular Events in Patients Who Undergo Chronic Hemodialysis: A Randomized, Placebo-Controlled Intervention Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 780-786.	2.2	132
32	Cardiovascular Disease in Early Stages of Chronic Kidney Disease in a Chinese Population. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 2617-2621.	3.0	49
33	P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. <i>Nephrology Dialysis Transplantation</i> , 2006, 22, 592-596.	0.4	259
34	Renal Function and Risk of Coronary Heart Disease in General Populations: New Prospective Study and Systematic Review. <i>PLoS Medicine</i> , 2007, 4, e270.	3.9	85
35	Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro towards a standardized approach for research on uraemia. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3381-3390.	0.4	74
36	Multifactorial intervention in metabolic syndrome targeting at prevention of chronic kidney disease ready for prime time?. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2768-2774.	0.4	8
37	Guanidino compounds after creatine supplementation in renal failure patients and their relation to inflammatory status. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 1330-1335.	0.4	26
38	Searching for biomarker patterns characterizing carotid atherosclerotic burden in patients with reduced renal function. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3521-3526.	0.4	32
39	Arterial stiffness and wave reflections in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3021-3027.	0.4	40
40	Effect of a Treatment Strategy Consisting of Pravastatin, Vitamin E, and Homocysteine Lowering on Carotid Intima-Media Thickness, Endothelial Function, and Renal Function in Patients With Mild to Moderate Chronic Kidney Disease. <i>Archives of Internal Medicine</i> , 2007, 167, 1262.	4.3	94

#	ARTICLE	IF	CITATIONS
41	Phenylacetic Acid and Arterial Vascular Properties in Patients with Chronic Kidney Disease Stage 5 on Hemodialysis Therapy. <i>Nephron Clinical Practice</i> , 2007, 107, c1-c6.	2.3	23
42	Pigmentation Markers: More Color in the Picture of Uremic Toxicity?. <i>Blood Purification</i> , 2007, 25, 480-482.	0.9	1
45	Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors. <i>Clinica Chimica Acta</i> , 2007, 379, 87-94.	0.5	47
47	The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. <i>European Heart Journal</i> , 2007, 28, 478-483.	1.0	157
48	The Kidney Disease: Improving Global Outcomes website: Comparison of guidelines as a tool for harmonization. <i>Kidney International</i> , 2007, 71, 1054-1061.	2.6	36
49	Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. <i>Kidney International</i> , 2007, 71, 31-38.	2.6	1,244
50	Complex Compartmental Behavior of Small Water-Soluble Uremic Retention Solutes: Evaluation by Direct Measurements in Plasma and Erythrocytes. <i>American Journal of Kidney Diseases</i> , 2007, 50, 279-288.	2.1	80
51	Increased urinary cystatin C reflects structural and functional renal tubular impairment independent of glomerular filtration rate. <i>Clinical Biochemistry</i> , 2007, 40, 946-951.	0.8	88
52	Coronary Artery Calcification and Chronically Decreased GFR in Living Kidney Donors. <i>American Journal of Kidney Diseases</i> , 2007, 49, 143-152.	2.1	19
53	Association Between Carotid Artery Intima-Media Thickness and Early-Stage CKD in a Chinese Population. <i>American Journal of Kidney Diseases</i> , 2007, 49, 786-792.	2.1	61
54	Bone health and vascular calcification relationships in chronic kidney disease. <i>International Urology and Nephrology</i> , 2007, 39, 1209-1216.	0.6	36
55	Relationship between renal function at the time of percutaneous coronary intervention and prognosis in ischemic heart disease patients. <i>Clinical and Experimental Nephrology</i> , 2007, 11, 56-60.	0.7	12
56	Correction of Anemia with Erythropoietin in Chronic Kidney Disease (stage 3 or 4): Effects on Cardiac Performance. <i>Cardiovascular Drugs and Therapy</i> , 2008, 22, 37-44.	1.3	33
57	What is new in uremic toxicity?. <i>Pediatric Nephrology</i> , 2008, 23, 1211-1221.	0.9	182
58	Doppler assessment of brachial artery flow as a measure of endothelial dysfunction in pediatric chronic renal failure. <i>Pediatric Nephrology</i> , 2008, 23, 2025-2030.	0.9	33
59	Prevalence and Factors Associated With CKD: A Population Study From Beijing. <i>American Journal of Kidney Diseases</i> , 2008, 51, 373-384.	2.1	250
60	Biomarker candidates for cardiovascular disease and bone metabolism disorders in chronic kidney disease: a systems biology perspective. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 1177-1187.	1.6	19
61	Chronic Kidney Disease After Hematopoietic Cell Transplantation: A Systematic Review. <i>American Journal of Transplantation</i> , 2008, 8, 2378-2390.	2.6	114

#	ARTICLE	IF	CITATIONS
63	Chronic Kidney Disease: Pathophysiology and Influence of Dietary Protein. , 2008, , 2615-2669.		0
65	Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. Atherosclerosis, 2008, 196, 823-834.	0.4	57
66	Positive Association between Plasma Homocysteine Level and Chronic Kidney Disease. Kidney and Blood Pressure Research, 2008, 31, 55-62.	0.9	18
67	Endothelial Function in Patients with Proteinuric Primary Glomerulonephritis. Nephron Clinical Practice, 2008, 109, c40-c47.	2.3	6
68	World Kidney Day 2008. Journal of the American Society of Nephrology: JASN, 2008, 19, 413-416.	3.0	3
69	Uraemic toxins and cardiovascular disease: in vitro research versus clinical outcome studies. CKJ: Clinical Kidney Journal, 2008, 1, 2-10.	1.4	11
70	Feast and Famine: Epidemiology and Clinical Trials in Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2008, 19, 2-4.	3.0	5
71	All high-flux membranes are equal but some high-flux membranes are less equal than others. Nephrology Dialysis Transplantation, 2008, 23, 1481-1483.	0.4	5
72	From Uremic Toxin Retention to Removal by Convection: Do We Know Enough?. , 2008, 161, 125-131.		17
73	Uremic Toxins: Do We Know Enough to Explain Uremia?. Blood Purification, 2008, 26, 77-81.	0.9	32
74	Predictors of change in estimated GFR: a population-based 7-year follow-up from the Tromso study. Nephrology Dialysis Transplantation, 2008, 23, 2818-2826.	0.4	81
75	A single session of haemodialysis improves left ventricular synchronicity in patients with end-stage renal disease: a pilot tissue synchronization imaging study. Nephrology Dialysis Transplantation, 2008, 23, 3622-3628.	0.4	21
76	A Bench to Bedside View of Uremic Toxins. Journal of the American Society of Nephrology: JASN, 2008, 19, 863-870.	3.0	287
77	Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 505-521.	2.2	472
78	Acute central haemodynamic effects induced by intraperitoneal glucose instillation. Nephrology Dialysis Transplantation, 2008, 23, 4029-4035.	0.4	12
79	New Strategies in Treatment of Mineral and Bone Disorders and Associated Cardiovascular Disease in Patients with Chronic Kidney Disease. Recent Patents on Cardiovascular Drug Discovery, 2008, 3, 222-228.	1.5	5
81	Management of hypertension in renal disease in pregnancy. , 0, , 149-166.		1
82	Chronic Kidney Disease as a Risk Factor for Coronary Artery Disease in Chinese with Type 2 Diabetes. American Journal of Nephrology, 2008, 28, 317-323.	1.4	14

#	ARTICLE	IF	CITATIONS
83	Low Serum Testosterone Increases Mortality Risk among Male Dialysis Patients. <i>Journal of the American Society of Nephrology</i> ; JASN, 2009, 20, 613-620.	3.0	167
84	High Prevalence of Intracranial Artery Calcification in Stroke Patients with CKD. <i>Clinical Journal of the American Society of Nephrology</i> ; CJASN, 2009, 4, 284-290.	2.2	59
85	Factors Associated with Vascular Stiffness: Cross-Sectional Analysis from the Chronic Renal Insufficiency Standards Implementation Study. <i>Nephron Clinical Practice</i> , 2009, 112, c190-c198.	2.3	14
86	Coronary Calcification in Patients with Chronic Kidney Disease and Coronary Artery Disease. <i>Clinical Journal of the American Society of Nephrology</i> ; CJASN, 2009, 4, 1892-1900.	2.2	194
87	Oxidative Modification of Albumin in Predialysis, Hemodialysis, and Peritoneal Dialysis Patients. <i>Nephron Clinical Practice</i> , 2009, 113, c234-c240.	2.3	21
88	Chronic Kidney Disease Is Often Unrecognized among Patients with Coronary Heart Disease: The REGARDS Cohort Study. <i>American Journal of Nephrology</i> , 2009, 29, 10-17.	1.4	32
89	Acute Central Hemodynamic Effects of Peritoneal Dialysis. <i>Contributions To Nephrology</i> , 2009, 163, 96-101.	1.1	1
90	Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 1429-1435.	0.4	124
91	Waist-to-Height Ratio Is the Best Anthropometric Index in Association with Adverse Cardiorenal Outcomes in Type 2 Diabetes Mellitus Patients. <i>American Journal of Nephrology</i> , 2009, 29, 615-619.	1.4	24
92	Impact of increasing haemodialysis frequency versus haemodialysis duration on removal of urea and guanidino compounds: a kinetic analysis. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2225-2232.	0.4	40
93	The plasticity of progenitor cells--why is it of interest to the nephrologists?. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2018-2020.	0.4	3
94	Mechanisms of Aortic and Cardiac Dysfunction in Uremic Mice With Aortic Calcification. <i>Circulation</i> , 2009, 119, 306-313.	1.6	49
95	Plasma Parathyroid Hormone Level and Prevalent Cardiovascular Disease in CKD Stages 3 and 4: An Analysis From the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2009, 53, S3-S10.	2.1	68
96	CKD and Mortality Risk in Older People: A Community-Based Population Study in the United Kingdom. <i>American Journal of Kidney Diseases</i> , 2009, 53, 950-960.	2.1	133
97	Kidney function and discrimination of cardiovascular risk in middle-aged men. <i>Journal of Internal Medicine</i> , 2009, 266, 406-413.	2.7	19
98	Chronic kidney disease: a new opportunity for better cardiovascular risk stratification. <i>Journal of Internal Medicine</i> , 2009, 266, 414-417.	2.7	0
99	PROGRESS IN UREMIC TOXIN RESEARCH: The Role of EUTox in Uremic Toxin Research. <i>Seminars in Dialysis</i> , 2009, 22, 323-328.	0.7	27
100	PROGRESS IN UREMIC TOXIN RESEARCH: The General Picture of Uremia. <i>Seminars in Dialysis</i> , 2009, 22, 329-333.	0.7	48

#	ARTICLE	IF	CITATIONS
101	PROGRESS IN UREMIC TOXIN RESEARCH: Phosphate Metabolism in Chronic Kidney Disease: From Pathophysiology to Clinical Management. <i>Seminars in Dialysis</i> , 2009, 22, 357-362.	0.7	15
102	PROGRESS IN UREMIC TOXIN RESEARCH: Adiponectin in Patients with Chronic Kidney Disease. <i>Seminars in Dialysis</i> , 2009, 22, 391-395.	0.7	39
103	PROGRESS IN UREMIC TOXIN RESEARCH: Endothelium and Vascular Smooth Muscle Cells in the Context of Uremia. <i>Seminars in Dialysis</i> , 2009, 22, 428-432.	0.7	24
104	PROGRESS IN UREMIC TOXIN RESEARCH: Conservative Treatment of the Uremic Syndrome. <i>Seminars in Dialysis</i> , 2009, 22, 449-453.	0.7	1
105	Chronic Kidney Disease Epidemic: Cost and Health Care Implications in China. <i>Seminars in Nephrology</i> , 2009, 29, 483-486.	0.6	29
106	Navigating Between the Scylla and Charybdis of Prescribing Dietary Protein for Chronic Kidney Diseases. <i>Annual Review of Nutrition</i> , 2009, 29, 341-364.	4.3	23
107	Association between Insulin Resistance and Carotid Arterial Stiffness in Nondiabetic Hemodialysis Patients. <i>Blood Purification</i> , 2009, 28, 193-199.	0.9	12
108	Pathophysiological mechanisms and consequences of cardiovascular calcifications: Role of uremic toxicity. <i>Annales Pharmaceutiques Francaises</i> , 2009, 67, 234-240.	0.4	16
109	Serum Indoxyl Sulfate Is Associated with Vascular Disease and Mortality in Chronic Kidney Disease Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1551-1558.	2.2	740
110	Renal and cardiac abnormalities in primary hypertension. <i>Journal of Hypertension</i> , 2009, 27, 1064-1073.	0.3	22
111	Elevated Serum Phosphate Predicts Mortality in Renal Transplant Recipients. <i>Transplantation</i> , 2009, 87, 1040-1044.	0.5	60
112	PREVALENCE OF CHRONIC RENAL FAILURE STAGE 3 OR MORE IN HIV-INFECTED PATIENTS IN ANTWERP: AN OBSERVATIONAL STUDY. <i>Acta Clinica Belgica</i> , 2010, 65, 392-398.	0.5	4
113	Pulse wave velocity and vascular calcification at different stages of chronic kidney disease. <i>Journal of Hypertension</i> , 2010, 28, 163-169.	0.3	141
114	Phosphate and vascular calcification: Emerging role of the sodium-dependent phosphate co-transporter PiT-1. <i>Thrombosis and Haemostasis</i> , 2010, 104, 464-470.	1.8	102
115	Circulating Plasma Antioxidants, Inflammatory Markers and Asymptomatic Carotid Atherosclerosis in End-Stage Renal Disease Patients: A Case Control Study. <i>International Journal of Immunopathology and Pharmacology</i> , 2010, 23, 327-334.	1.0	7
116	Predicting cardiovascular disease morbidity and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a prospective, multicenter, observational cohort study. <i>BMC Nephrology</i> , 2010, 11, 14.	0.8	72
117	Prognostic Study of Cardiac and Renal Events in Japanese Patients With Chronic Kidney Disease and Cardiovascular Risk Using Myocardial Perfusion SPECT: J-ACCESS 3 Study Design. <i>Therapeutic Apheresis and Dialysis</i> , 2010, 14, 379-385.	0.4	10
118	Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. <i>Journal of Internal Medicine</i> , 2010, 268, 456-467.	2.7	281

#	ARTICLE	IF	CITATIONS
119	AGEs/RAGE in CKD: irreversible metabolic memory road toward CVD?. European Journal of Clinical Investigation, 2010, 40, 623-635.	1.7	44
120	New horizons in vascular biology and thrombosis: Highlights from EMVBM 2009. Thrombosis and Haemostasis, 2010, 104, 421-423.	1.8	4
121	Estudo epidemiol3gico da doen3a renal cr3nica terminal no oeste do Paran3; uma experi3ncia de 878 casos atendidos em 25 anos. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2010, 32, 51-56.	0.4	13
122	Advantages of New Hemodialysis Membranes and Equipment. Nephron Clinical Practice, 2010, 114, c165-c172.	2.3	30
123	Guanidino Compounds as Cause of Cardiovascular Damage in Chronic Kidney Disease: An in vitro Evaluation. Blood Purification, 2010, 30, 277-287.	0.9	49
124	Cardiovascular Disease in Chronic Kidney Disease. , 2010, , 935-950.		4
125	Endogenous Testosterone and Mortality in Male Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2018-2023.	2.2	80
126	Heart rate recovery after exercise is associated with renal function in patients with a homogenous chronic renal disease. Nephrology Dialysis Transplantation, 2010, 25, 509-513.	0.4	9
127	Dinucleoside polyphosphates: newly detected uraemic compounds with an impact on leucocyte oxidative burst. Nephrology Dialysis Transplantation, 2010, 25, 2636-2644.	0.4	10
128	The five most cited NDT papers from 2005 to 2009. Nephrology Dialysis Transplantation, 2010, 25, 2825-2831.	0.4	0
129	The Gut: The Forgotten Organ in Uremia?. Blood Purification, 2010, 29, 130-136.	0.9	139
130	Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrology Dialysis Transplantation, 2010, 25, 1183-1191.	0.4	371
131	Atherosclerosis in CKD: differences from the general population. Nature Reviews Nephrology, 2010, 6, 723-735.	4.1	174
132	Uremic Toxins. , 2010, , 219-234.		0
133	Guanidino compounds inhibit acetylcholinesterase and butyrylcholinesterase activities: Effect neuroprotector of vitamins E plus C. International Journal of Developmental Neuroscience, 2010, 28, 465-473.	0.7	45
134	Noninvasive evaluation of large artery function and structure in dialysis patients: Clinical applications. Artery Research, 2010, 4, 138.	0.3	0
135	Albuminuria is strongly associated with arterial stiffness, especially in diabetic or hypertensive subjects3A population-based study (Taichung Community Health Study, TCHS). Atherosclerosis, 2010, 211, 315-321.	0.4	46
136	Prognostic value of chronic kidney disease in patients with coronary heart disease: Role of estimating equations. Atherosclerosis, 2010, 211, 342-347.	0.4	22

#	ARTICLE	IF	CITATIONS
137	Serum levels of total p-cresylsulphate are associated with angiographic coronary atherosclerosis severity in stable angina patients with early stage of renal failure. <i>Atherosclerosis</i> , 2010, 211, 579-583.	0.4	69
138	Uraemic toxins for consideration by the cardiologistâ€”Beyond traditional and non-traditional cardiovascular risk factors. <i>Atherosclerosis</i> , 2010, 211, 381-383.	0.4	18
139	Bone morphogenetic protein-2 may represent the molecular link between oxidative stress and vascular stiffness in chronic kidney disease. <i>Atherosclerosis</i> , 2010, 211, 418-423.	0.4	56
140	Epicardial Adipose Tissue and Coronary Artery Calcification in Diabetic and Nondiabetic End-Stage Renal Disease Patients. <i>Renal Failure</i> , 2011, 33, 770-775.	0.8	28
141	Direct Effects of Phosphate on Vascular Cell Function. <i>Advances in Chronic Kidney Disease</i> , 2011, 18, 105-112.	0.6	103
142	Glomerular filtration rate and 10-year mortality in a 70-year-old community-dwelling Japanese population. <i>Aging Clinical and Experimental Research</i> , 2011, 23, 223-230.	1.4	0
143	Elastin Degradation and Vascular Smooth Muscle Cell Phenotype Change Precede Cell Loss and Arterial Medial Calcification in a Uremic Mouse Model of Chronic Kidney Disease. <i>American Journal of Pathology</i> , 2011, 178, 764-773.	1.9	149
144	Symmetric Dimethylarginine as a Proinflammatory Agent in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2374-2383.	2.2	119
145	The effect of n-3 polyunsaturated fatty acids on leukotriene B4 and leukotriene B5 production from stimulated neutrophil granulocytes in patients with chronic kidney disease. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2011, 85, 37-41.	1.0	27
147	Serum S100A12 (EN-RAGE) Levels in Patients with Decreased Renal Function and Subclinical Chronic Inflammatory Disease. <i>Kidney and Blood Pressure Research</i> , 2011, 34, 457-464.	0.9	14
148	Connection Between the Early Phases of Kidney Disease and the Metabolic Syndrome. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011, 64, 373-378.	0.4	6
149	High circulating levels of large splice variants of tenascin-C is associated with mortality and cardiovascular disease in chronic kidney disease patients. <i>Atherosclerosis</i> , 2011, 215, 116-124.	0.4	23
150	Antiatherogenic effect of pioglitazone on uremic apolipoprotein E knockout mice by modulation of the balance of regulatory and effector T cells. <i>Atherosclerosis</i> , 2011, 218, 330-338.	0.4	11
151	A Review of Sevelamer Hydrochloride in End-Stage Renal Disease Patients on Dialysis. <i>Clinical Medicine Insights Therapeutics</i> , 2011, 3, CMT.S5990.	0.4	1
152	Is Chronic Kidney Disease Associated with a High Ankle Brachial Index in Adults at High Cardiovascular Risk?. <i>Journal of Atherosclerosis and Thrombosis</i> , 2011, 18, 224-230.	0.9	12
153	Estimated Glomerular Filtration Rate and the Risk of Major Vascular Events and All-Cause Mortality: A Meta-Analysis. <i>PLoS ONE</i> , 2011, 6, e25920.	1.1	70
154	Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2011, 20, 146-152.	1.0	11
155	Coronary artery calcification and coronary ischaemia in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 720-726.	0.4	21

#	ARTICLE	IF	CITATIONS
156	Determinants of Serum High Molecular Weight (HMW) Adiponectin Levels in Patients with Coronary Artery Disease: Associations with Cardio-renal-anemia Syndrome. <i>Internal Medicine</i> , 2011, 50, 2953-2960.	0.3	15
157	Predicting hospital cost in CKD patients through blood chemistry values. <i>BMC Nephrology</i> , 2011, 12, 65.	0.8	6
158	Detection of urinary abnormalities in a community from northern Italy based on the World Kidney Day screening program. <i>International Urology and Nephrology</i> , 2011, 43, 793-799.	0.6	2
159	Chronic kidney disease-related atherosclerosis - proteomic studies of blood plasma. <i>Proteome Science</i> , 2011, 9, 25.	0.7	45
160	Proteomics in chronic kidney disease: The issues clinical nephrologists need an answer for. <i>Proteomics - Clinical Applications</i> , 2011, 5, 233-240.	0.8	20
161	Update on the Pharmacokinetics and Redox Properties of Protein-Bound Uremic Toxins. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 3682-3695.	1.6	95
162	Monitoring of inflammation in patients on dialysis: forewarned is forearmed. <i>Nature Reviews Nephrology</i> , 2011, 7, 166-176.	4.1	106
163	Fibrinogen, Hematocrit, Platelets in Mild Kidney Dysfunction and the Role of Uric Acid: An Italian Male Population Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011, 17, 58-65.	0.7	8
164	Markers of vascular disease in plasma from patients with chronic kidney disease identified by proteomic analysis. <i>Journal of Hypertension</i> , 2011, 29, 783-790.	0.3	33
165	Statins and Lipid- Lowering Strategies in Cardiorenal Patients. <i>Contributions To Nephrology</i> , 2011, 171, 143-150.	1.1	7
166	Acute kidney injury following HCT: incidence, risk factors and outcome. <i>Bone Marrow Transplantation</i> , 2011, 46, 1399-1408.	1.3	58
167	Nurse-Coordinated Care in CKD: Time for Translation into Practice?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1229-1231.	2.2	3
168	Lipotoxicity and cardiac dysfunction in mammals and <i>Drosophila</i> . <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2011, 46, 376-385.	2.3	36
169	Vitamin D Receptor Activators and Clinical Outcomes in Chronic Kidney Disease. <i>International Journal of Nephrology</i> , 2011, 2011, 1-13.	0.7	18
170	Elevated Pro-Brain Natriuretic Peptide, Troponin T and Malnutrition Inflammatory Score in Chronic Hemodialysis Patients with Overt Cardiovascular Disease. <i>Nephron Clinical Practice</i> , 2011, 117, c198-c205.	2.3	12
171	Protein-Bound Uremic Toxins: New Insight from Clinical Studies. <i>Toxins</i> , 2011, 3, 911-919.	1.5	103
172	Does Uremia Cause Vascular Dysfunction. <i>Kidney and Blood Pressure Research</i> , 2011, 34, 284-290.	0.9	122
173	The Arteriovenous Fistula: Lesser Evil or God's Blessing?. <i>Blood Purification</i> , 2011, 32, 253-253.	0.9	3

#	ARTICLE	IF	CITATIONS
174	Cardiorenal Syndrome Type 4 – Cardiovascular Disease in Patients with Chronic Kidney Disease: Epidemiology, Pathogenesis, and Management. <i>International Journal of Nephrology</i> , 2011, 2011, 1-8.	0.7	24
176	Improving CKD-MBD management in haemodialysis patients: barrier analysis for implementing better practice. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1319-1326.	0.4	39
177	Warning: the unfortunate end of p-cresol as a uraemic toxin. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1464-1467.	0.4	86
178	The role of collagen metabolism in CKD-associated arterial senescence: underestimated and underappreciated. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2726-2728.	0.4	5
179	Association of standardized estimated glomerular filtration rate with the prevalence of hypertension among adults in the United States. <i>Journal of Human Hypertension</i> , 2011, 25, 469-475.	1.0	5
180	Does a standardization of GFR estimation increase the accuracy of cardiovascular risk assessment?. <i>Journal of Human Hypertension</i> , 2011, 25, 467-468.	1.0	0
181	Low serum testosterone, arterial stiffness and mortality in male haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2971-2977.	0.4	82
182	The Phosphorus and the Vascular Calcification in ESRD between Old Adventures and New Horizons. <i>International Journal of Nephrology</i> , 2011, 2011, 1-1.	0.7	0
183	Interactions between CKD and MetS and the Development of CVD. <i>Cardiology Research and Practice</i> , 2011, 2011, 1-2.	0.5	3
184	Chronic renal failure alters endothelial function in cerebral circulation in mice. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 301, H1143-H1152.	1.5	34
185	Metabolic Syndrome, Chronic Kidney, and Cardiovascular Diseases: Role of Adipokines. <i>Cardiology Research and Practice</i> , 2011, 2011, 1-11.	0.5	55
186	Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease: A Dynamic and Life-Threatening Triad. <i>Cardiology Research and Practice</i> , 2011, 2011, 1-16.	0.5	29
187	Immune Dysfunction in Uremia – An Update. <i>Toxins</i> , 2012, 4, 962-990.	1.5	127
188	Dimethylarginine – biomarkers in progression of kidney disease / Dimetilarginini – biomarkeri u progresiji bubrežnih oboljenja. <i>Journal of Medical Biochemistry</i> , 2012, 31, 301-308.	0.7	6
189	Diverging Association of Reduced Glomerular Filtration Rate and Albuminuria With Coronary and Noncoronary Events in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 143-149.	4.3	107
190	How do laboratory specialists advise clinicians concerning the use and interpretation of renal tests?. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2012, 72, 143-151.	0.6	8
191	Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. <i>Kidney International</i> , 2012, 82, 1297-1303.	2.6	134
192	The Development of Our Understanding of Uremia. , 2012, , 3-12.		0

#	ARTICLE	IF	CITATIONS
193	Serum Levels of Omentin in End-Stage Renal Disease Patients. <i>Kidney and Blood Pressure Research</i> , 2012, 35, 511-516.	0.9	34
194	Pro: The arteriovenous fistula is a blessing of God. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3752-3756.	0.4	26
195	Biomarkers Determining Cardiovascular Risk in Patients with Kidney Disease. <i>Current Medicinal Chemistry</i> , 2012, 19, 2555-2571.	1.2	13
196	Increased Prevalence and Severity of Coronary Artery Calcification in Patients with Chronic Kidney Disease Stage III and IV. <i>Nephron Extra</i> , 2012, 2, 192-204.	1.1	14
197	Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on arterial compliance and distensibility in patients with mild-to-moderate chronic kidney disease. <i>Clinical Nephrology</i> , 2012, 78, 263-272.	0.4	8
198	The role of protein-bound uremic toxins on peripheral artery disease and vascular access failure in patients on hemodialysis. <i>Atherosclerosis</i> , 2012, 225, 173-179.	0.4	57
200	Insulin Resistance and Left Ventricular Mass in Non-Diabetic Hemodialysis Patients. <i>Current Therapeutic Research</i> , 2012, 73, 165-173.	0.5	3
201	Applying estimated glomerular filtration rate to an ageing population: are we in danger of becoming ageist?. <i>European Journal of Internal Medicine</i> , 2012, 23, 705-710.	1.0	2
202	Prognostic Implications of Plasma Myoglobin Levels in Patients with Chronic Kidney Disease. <i>International Journal of Artificial Organs</i> , 2012, 35, 959-968.	0.7	1
203	The association between thyroid hormones and arterial stiffness in peritoneal dialysis patients. <i>International Urology and Nephrology</i> , 2012, 44, 601-606.	0.6	41
204	FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. <i>Osteoporosis International</i> , 2012, 23, 2017-2025.	1.3	184
205	Effects of indoxyl sulfate on adherens junctions of endothelial cells and the underlying signaling mechanism. <i>Journal of Cellular Biochemistry</i> , 2012, 113, 1034-1043.	1.2	42
206	Association of insulin resistance with arterial stiffness in nondiabetic peritoneal dialysis patients. <i>International Urology and Nephrology</i> , 2012, 44, 255-262.	0.6	17
207	A novel UPLC-MS/MS method for simultaneous determination of seven uremic retention toxins with cardiovascular relevance in chronic kidney disease patients. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 1937-1947.	1.9	47
208	Renal function, calcium regulation, and time to hospitalization of patients with chronic kidney disease. <i>BMC Nephrology</i> , 2013, 14, 154.	0.8	2
209	Soluble TWEAK independently predicts atherosclerosis in renal transplant patients. <i>BMC Nephrology</i> , 2013, 14, 144.	0.8	24
210	Glomerular filtration rate and albuminuria predict mortality independently from coronary artery calcified plaque in the Diabetes Heart Study. <i>Cardiovascular Diabetology</i> , 2013, 12, 68.	2.7	15
211	Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. <i>Kidney International</i> , 2013, 84, 733-744.	2.6	205

#	ARTICLE	IF	CITATIONS
212	Endothelial dysfunction, inflammation and malnutrition markers as predictors of mortality in dialysis patients: multimarker approach. <i>International Urology and Nephrology</i> , 2013, 45, 1715-1724.	0.6	18
213	The risk of atherosclerosis in patients with chronic kidney disease. <i>International Urology and Nephrology</i> , 2013, 45, 1605-1612.	0.6	76
214	Oxidative stress in patients treated with continuous ambulatory peritoneal dialysis (CAPD) and the significant role of vitamin C and E supplementation. <i>International Urology and Nephrology</i> , 2013, 45, 1137-1144.	0.6	36
215	Internet-Based Tools to Assess Diet and Provide Feedback in Chronic Kidney Disease Stage IV: A Pilot Study. , 2013, 23, e33-e42.		8
216	Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1874-1888.	0.4	24
217	Effects of sevelamer treatment on cardiovascular abnormalities in mice with chronic renal failure. <i>Kidney International</i> , 2013, 84, 491-500.	2.6	50
218	The contribution of thyroid dysfunction on cardiovascular disease in patients with chronic kidney disease. <i>Atherosclerosis</i> , 2013, 227, 26-31.	0.4	14
220	Cardiovascular disease in peritoneal dialysis: A review. <i>Clinical Queries Nephrology</i> , 2013, 2, 152-155.	0.2	1
221	Cardiovascular readmissions and excess costs following percutaneous coronary intervention in patients with chronic kidney disease: Data from a large multi-centre Australian registry. <i>International Journal of Cardiology</i> , 2013, 168, 2783-2790.	0.8	13
222	Uremia-Related Oxidative Stress in Leukocytes Is Not Triggered by Î²2-Microglobulin. , 2013, 23, 456-463.		9
223	ADMA and C-reactive protein as mortality predictors in dialysis patients. <i>Open Medicine (Poland)</i> , 2013, 8, 346-353.	0.6	2
224	Chronic Kidney Disease: A Clinical Model of Premature Aging. <i>American Journal of Kidney Diseases</i> , 2013, 62, 339-351.	2.1	237
225	Relation between serum estradiol levels and mortality in postmenopausal female hemodialysis patients. <i>International Urology and Nephrology</i> , 2013, 45, 503-510.	0.6	11
226	A Randomized Trial of Dietary Sodium Restriction in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 2096-2103.	3.0	253
227	Protein-Bound Uremic Toxins Stimulate Crosstalk between Leukocytes and Vessel Wall. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1981-1994.	3.0	96
228	An update on uremic toxins. <i>International Urology and Nephrology</i> , 2013, 45, 139-150.	0.6	134
229	Calcium, Phosphate, PTH, Vitamin D and FGF-23 in Chronic Kidney Disease. , 2013, , 263-283.		2
230	Homocysteine and C-Reactive Protein as Useful Surrogate Markers for Evaluating CKD Risk in Adults. <i>Kidney and Blood Pressure Research</i> , 2013, 37, 402-413.	0.9	12

#	ARTICLE	IF	CITATIONS
231	The Evidence of Occult Hypervolemia; Improvement of Cardiac Functions After Kidney Transplantation. <i>Renal Failure</i> , 2013, 35, 718-720.	0.8	2
232	The clinical impact of plasma leptin levels in a cohort of chronic kidney disease patients. <i>CKJ: Clinical Kidney Journal</i> , 2013, 6, 63-70.	1.4	16
233	Arteriovenous access failure: more than just intimal hyperplasia?. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1085-1092.	0.4	110
234	Relationship between glomerular dysfunction and left-ventricular mass independent of haemodynamic factors in a community sample. <i>Journal of Hypertension</i> , 2013, 31, 568-575.	0.3	7
235	Serum p-cresyl sulfate predicts cardiovascular disease and mortality in elderly hemodialysis patients. <i>Archives of Medical Science</i> , 2013, 4, 662-668.	0.4	43
236	Alternative Splicing Events Is Not a Key Event for Gene Expression Regulation in Uremia. <i>PLoS ONE</i> , 2013, 8, e82702.	1.1	0
237	Heritable Influence of DBH on Adrenergic and Renal Function: Twin and Disease Studies. <i>PLoS ONE</i> , 2013, 8, e82956.	1.1	12
239	AST-120 for the management of progression of chronic kidney disease. <i>International Journal of Nephrology and Renovascular Disease</i> , 2014, 7, 49.	0.8	53
240	Renal Nerve Ablation for Hypertensive Patients with Chronic Kidney Disease. <i>Current Vascular Pharmacology</i> , 2014, 12, 47-54.	0.8	11
241	Association Between Plasma Beta-2 Microglobulin Level and Cardiac Performance in Patients With Chronic Kidney Disease. <i>Nephro-Urology Monthly</i> , 2014, 7, e23563.	0.0	8
242	The Aryl Hydrocarbon Receptor-Activating Effect of Uremic Toxins from Tryptophan Metabolism: A New Concept to Understand Cardiovascular Complications of Chronic Kidney Disease. <i>Toxins</i> , 2014, 6, 934-949.	1.5	194
243	Neurological Disorders in a Murine Model of Chronic Renal Failure. <i>Toxins</i> , 2014, 6, 180-193.	1.5	10
244	Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. <i>Kidney International</i> , 2014, 86, 1213-1220.	2.6	123
245	Differential Effects of Indoxyl Sulfate and Inorganic Phosphate in a Murine Cerebral Endothelial Cell Line (bEnd.3). <i>Toxins</i> , 2014, 6, 1742-1760.	1.5	45
246	Preliminary study of Huai Qi Huang granules delay the development of primary glomerular diseases in human. <i>Renal Failure</i> , 2014, 36, 1407-1410.	0.8	7
247	Serum Omentin-1 Levels in Diabetic and Nondiabetic Patients with Chronic Kidney Disease. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2014, 122, 451-456.	0.6	42
248	Association of Pulse Wave Velocity and Pulse Pressure With Decline in Kidney Function. <i>Journal of Clinical Hypertension</i> , 2014, 16, 372-377.	1.0	35
249	Modulation of NADPH^+ oxidase activity by known uraemic retention solutes. <i>European Journal of Clinical Investigation</i> , 2014, 44, 802-811.	1.7	10

#	ARTICLE	IF	CITATIONS
250	Is Alcohol Drinking Associated with Renal Impairment in the General Population of South Korea?. <i>Kidney and Blood Pressure Research</i> , 2014, 39, 40-49.	0.9	10
251	Progression of Coronary Artery Calcification in Living Kidney Donors: A Follow-Up Study. <i>Nephron Clinical Practice</i> , 2014, 126, 144-150.	2.3	6
252	Uremic Toxins and Lipases in Haemodialysis: A Process of Repeated Metabolic Starvation. <i>Toxins</i> , 2014, 6, 1505-1511.	1.5	10
253	Chronic Kidney Disease and Nonalcoholic Fatty Liver Disease—Is There a Link?. <i>Gastroenterology Research and Practice</i> , 2014, 2014, 1-6.	0.7	44
254	Non-Alcoholic Fatty Liver Disease Proven by Transient Elastography in Hemodialysis Patients: Is It a New Risk Factor for Adverse Cardiovascular Events?. <i>Blood Purification</i> , 2014, 37, 259-265.	0.9	18
255	The Risk of Ischemic Stroke after an Acute Myocardial Infarction in Patients with Decreased Renal Function. <i>Cerebrovascular Diseases</i> , 2014, 37, 460-469.	0.8	9
256	Contribution of impaired renal function to cardiovascular risk prediction models in renal transplant recipients. <i>Clinical Transplantation</i> , 2014, 28, 1383-1392.	0.8	3
257	The effect of lipoic acid on cyanate toxicity in the rat heart. <i>Pharmacological Reports</i> , 2014, 66, 87-92.	1.5	2
258	Implications of Kidney Disease in the Cardiac Patient. <i>Interventional Cardiology Clinics</i> , 2014, 3, 317-331.	0.2	0
259	Serum total p-cresylsulfate level is associated with abnormal QTc interval in stable angina patients with early stage of renal failure. <i>Clinica Chimica Acta</i> , 2014, 437, 25-30.	0.5	12
260	Should screening of renal markers be recommended in a working population?. <i>International Urology and Nephrology</i> , 2014, 46, 1601-1608.	0.6	2
261	New therapeutic perspectives on protein-bound uremic toxins in chronic kidney disease. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 109-113.	1.5	2
262	The Uremic Toxicity of Indoxyl Sulfate and p-Cresyl Sulfate. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1897-1907.	3.0	525
263	Nonalcoholic fatty liver disease (NAFLD): A new risk factor for adverse cardiovascular events in dialysis patients. <i>Medical Hypotheses</i> , 2014, 82, 205-208.	0.8	24
264	Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. <i>Lancet, The</i> , 2014, 383, 1831-1843.	6.3	341
265	Predictors of long-term outcome of percutaneous coronary intervention in octogenarians with acute coronary syndrome. <i>International Journal of Cardiology Heart & Vessels</i> , 2014, 4, 138-144.	0.5	1
266	Reduction in sodium intake is independently associated with improved blood pressure control in people with chronic kidney disease in primary care. <i>British Journal of Nutrition</i> , 2015, 114, 936-942.	1.2	11
267	High cut-off dialysis in chronic haemodialysis patients. <i>European Journal of Clinical Investigation</i> , 2015, 45, 1333-1340.	1.7	31

#	ARTICLE	IF	CITATIONS
268	Tissue Characterization of Coronary Plaques as a Key to Reno-Cardiac Syndrome. <i>Circulation Journal</i> , 2015, 79, 1691-1692.	0.7	0
269	Role of Gut-Derived Protein-Bound Uremic Toxins in Cardiorenal Syndrome and Potential Treatment Modalities. <i>Circulation Journal</i> , 2015, 79, 2088-2097.	0.7	36
270	Human proximal tubule epithelial cells cultured on hollow fibers: living membranes that actively transport organic cations. <i>Scientific Reports</i> , 2015, 5, 16702.	1.6	90
271	Urinary Protein Biomarkers in Chronic Kidney Disease. <i>BANTAO Journal</i> , 2015, 13, 1-3.	0.1	0
272	A competing risk analysis of sequential complication development in Asian type 2 diabetes mellitus patients. <i>Scientific Reports</i> , 2015, 5, 15687.	1.6	20
273	Approximation of Corrected Calcium Concentrations in Advanced Chronic Kidney Disease Patients with or without Dialysis Therapy. <i>Nephron Extra</i> , 2015, 5, 39-49.	1.1	9
274	Adherence to phosphate binders: improving patient engagement. <i>Journal of Renal Nursing</i> , 2015, 7, 168-174.	0.1	0
275	Impact of anaemia treatment for left ventricular remodelling prior to initiation of dialysis in chronic kidney disease patients: Efficacy and stability of long acting erythropoietin stimulating agents. <i>Nephrology</i> , 2015, 20, 7-13.	0.7	5
276	Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. <i>World Journal of Gastroenterology</i> , 2015, 21, 6820-6834.	1.4	120
277	The Effects of Omega-3 Fatty Acid on Vitamin D Activation in Hemodialysis Patients: A Pilot Study. <i>Marine Drugs</i> , 2015, 13, 741-755.	2.2	28
278	Chronic Kidney Disease and Fibrosis: The Role of Uremic Retention Solutes. <i>Frontiers in Medicine</i> , 2015, 2, 60.	1.2	52
279	Influence of Malondialdehyde and Matrix Metalloproteinase-9 on Progression of Carotid Atherosclerosis in Chronic Renal Disease with Cardiometabolic Syndrome. <i>Mediators of Inflammation</i> , 2015, 2015, 1-8.	1.4	8
280	Aortic Arch Calcification Predicts the Renal Function Progression in Patients with Stage 3 to 5 Chronic Kidney Disease. <i>BioMed Research International</i> , 2015, 2015, 1-7.	0.9	16
281	Lipoprotein profile, lipoprotein-associated phospholipase A2 and cardiovascular risk in hemodialysis patients. <i>Journal of Nephrology</i> , 2015, 28, 749-755.	0.9	12
282	Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1449-1461.	0.9	43
283	Improving the identification and management of chronic kidney disease in primary care: lessons from a staged improvement collaborative. <i>International Journal for Quality in Health Care</i> , 2015, 27, 10-16.	0.9	15
284	Complete Low-Intensity Endurance Training Programme in Haemodialysis Patients: Improving the Care of Renal Patients. <i>Nephron Clinical Practice</i> , 2015, 128, 387-393.	2.3	22
285	Urea-induced ROS cause endothelial dysfunction in chronic renal failure. <i>Atherosclerosis</i> , 2015, 239, 393-400.	0.4	83

#	ARTICLE	IF	CITATIONS
286	Incremental prognostic value of kidney function decline over coronary artery disease for cardiovascular event prediction after coronary computed tomography. <i>Kidney International</i> , 2015, 88, 152-159.	2.6	18
287	Colestilan for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. <i>Expert Review of Endocrinology and Metabolism</i> , 2015, 10, 131-142.	1.2	1
288	Distinct Effects of Inorganic Phosphate on Cell Cycle and Apoptosis in Human Vascular Smooth Muscle Cells. <i>Journal of Cellular Physiology</i> , 2015, 230, 347-355.	2.0	26
289	New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1842-1852.	0.4	64
290	Association of serum phosphorus with subclinical atherosclerosis in chronic kidney disease. Sex makes a difference. <i>Atherosclerosis</i> , 2015, 241, 264-270.	0.4	35
291	Usefulness of liver test and controlled attenuation parameter in detection of nonalcoholic fatty liver disease in patients with chronic renal failure and coronary heart disease. <i>Wiener Klinische Wochenschrift</i> , 2015, 127, 451-458.	1.0	14
292	Renal impairment among postmenopausal women with osteoporosis from a large health plan in Israel. <i>Archives of Osteoporosis</i> , 2015, 10, 210.	1.0	5
293	Vascular Effects of Inflammation and Oxidative Stress in CKD. , 2015, , 51-59.		0
294	Coronary Heart Disease Risk Factors and Outcomes in the Twenty-First Century: Findings from the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. <i>Current Hypertension Reports</i> , 2015, 17, 541.	1.5	21
295	Usefulness of Beta2-Microglobulin as a Predictor of All-Cause and Nonculprit Lesion-Related Cardiovascular Events in Acute Coronary Syndromes (from the PROSPECT Study). <i>American Journal of Cardiology</i> , 2015, 116, 1034-1040.	0.7	10
296	GC analysis of guanidino compounds in serum and urine of healthy volunteers and uremic patients using methylglyoxal and ethyl chloroformate as derivatizing reagent. <i>Analytical Methods</i> , 2015, 7, 7724-7732.	1.3	0
297	Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. <i>Kidney International</i> , 2015, 87, 649-659.	2.6	158
299	High sodium intake is associated with important risk factors in a large cohort of chronic kidney disease patients. <i>European Journal of Clinical Nutrition</i> , 2015, 69, 786-790.	1.3	34
300	Nutritional treatment in chronic kidney disease: the concept of nephroprotection. <i>Clinical and Experimental Nephrology</i> , 2015, 19, 161-167.	0.7	18
301	The Uremic Syndrome. , 2015, , 83-91.		1
302	N-methyl-2-pyridone-5-carboxamide (2PY)â€”Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin. <i>Toxins</i> , 2016, 8, 339.	1.5	42
303	Determination of Asymmetric and Symmetric Dimethylarginine in Serum from Patients with Chronic Kidney Disease: UPLC-MS/MS versus ELISA. <i>Toxins</i> , 2016, 8, 149.	1.5	26
304	Significance of the DNA-Histone Complex Level as a Predictor of Major Adverse Cardiovascular Events in Hemodialysis Patients: The Effect of Uremic Toxin on DNA-Histone Complex Formation. <i>Blood Purification</i> , 2016, 41, 64-71.	0.9	10

#	ARTICLE	IF	CITATIONS
306	Angiotensin-2, Angiotensin-1 and subclinical cardiovascular disease in Chronic Kidney Disease. <i>Scientific Reports</i> , 2016, 6, 39400.	1.6	29
307	Clinical management of the uraemic syndrome in chronic kidney disease. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 360-373.	5.5	78
308	Assessing longitudinal trends in cardiac function among pediatric patients with chronic kidney disease. <i>Pediatric Nephrology</i> , 2016, 31, 1485-1497.	0.9	5
309	New Method for the Approximation of Corrected Calcium Concentrations in Chronic Kidney Disease Patients. <i>Therapeutic Apheresis and Dialysis</i> , 2016, 20, 46-52.	0.4	12
310	Sources of Mortality on Dialysis with an Emphasis on Microemboli. <i>Seminars in Dialysis</i> , 2016, 29, 442-446.	0.7	10
311	Novel regulations of MEF2-A, MEF2-D, and CACNA1S in the functional incompetence of adipose-derived mesenchymal stem cells by induced indoxyl sulfate in chronic kidney disease. <i>Cytotechnology</i> , 2016, 68, 2589-2604.	0.7	7
312	High cut-off dialysis in chronic haemodialysis patients reduces serum procalcific activity. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1706-1712.	0.4	26
313	Influence of Kidney Function on Blood Pressure Response to Lifestyle Modifications: Secondary Analysis From the Exercise and Nutritional Interventions for Cardiovascular Health (ENCORE) Trial. <i>Journal of Clinical Hypertension</i> , 2016, 18, 1260-1267.	1.0	5
314	Oxidative Stress Is Involved in the Renal Dysfunction Induced by Sinoaortic Denervation in Rats. <i>Chemical and Pharmaceutical Bulletin</i> , 2016, 64, 1458-1465.	0.6	6
315	Levels of Indoxyl Sulfate in Kidney Transplant Patients, and the Relationship With Hard Outcomes. <i>Circulation Journal</i> , 2016, 80, 722-730.	0.7	28
316	Competing risk of death and end-stage renal disease in incident chronic kidney disease (stages 3 to 5): the EPIRAN community-based study. <i>BMC Nephrology</i> , 2016, 17, 174.	0.8	8
317	Serum microRNAs are altered in various stages of chronic kidney disease: a preliminary study. <i>CKJ: Clinical Kidney Journal</i> , 2016, 10, sfw060.	1.4	14
318	LC-MS/MS method for simultaneous determination of serum cresyl sulfate and indoxyl sulfate in patients undergoing peritoneal dialysis. <i>Biomedical Chromatography</i> , 2016, 30, 1782-1788.	0.8	28
319	Monocytic angiotensin-converting enzyme 2 relates to atherosclerosis in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw206.	0.4	42
320	Effect of colestilan on serum phosphorus in dialysis patients: A meta-analysis of the literature. <i>Nephrology</i> , 2016, 21, 229-235.	0.7	0
321	Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study. <i>Journal of Nephrology</i> , 2016, 29, 71-78.	0.9	22
322	Indoxyl sulfate promotes vascular smooth muscle cell calcification via the JNK/Pit-1 pathway. <i>Renal Failure</i> , 2016, 38, 1702-1710.	0.8	31
323	Contrast-induced nephropathy following angiography and cardiac interventions. <i>Heart</i> , 2016, 102, 638-648.	1.2	160

#	ARTICLE	IF	CITATIONS
324	FGF-23 levels are associated with vascular calcification, but not with atherosclerosis, in hemodialysis patients. <i>International Urology and Nephrology</i> , 2016, 48, 609-617.	0.6	23
325	Future Avenues to Decrease Uremic Toxin Concentration. <i>American Journal of Kidney Diseases</i> , 2016, 67, 664-676.	2.1	72
326	Association of advanced age with concentrations of uraemic toxins in CKD. <i>Journal of Nephrology</i> , 2016, 29, 81-91.	0.9	10
327	The chronic kidney disease "Mineral bone disorder (CKD-MBD): Advances in pathophysiology. <i>Bone</i> , 2017, 100, 80-86.	1.4	136
328	Endothelial maintenance in health and disease: Importance of sex differences. <i>Pharmacological Research</i> , 2017, 119, 48-60.	3.1	31
329	Uremia modulates the phenotype of aortic smooth muscle cells. <i>Atherosclerosis</i> , 2017, 257, 64-70.	0.4	11
330	PCSK9 in chronic kidney disease. <i>International Urology and Nephrology</i> , 2017, 49, 1015-1024.	0.6	41
331	Plasma protein-bound di-tyrosines as biomarkers of oxidative stress in end stage renal disease patients on maintenance haemodialysis. <i>BBA Clinical</i> , 2017, 7, 55-63.	4.1	16
332	High density lipoprotein (HDL) particles from end-stage renal disease patients are defective in promoting reverse cholesterol transport. <i>Scientific Reports</i> , 2017, 7, 41481.	1.6	25
333	Vasculopathy in the setting of cardiorenal syndrome: roles of protein-bound uremic toxins. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2017, 313, H1-H13.	1.5	36
334	Pulse Pressure, Instead of Brachium-Ankle Pulse Wave Velocity, is Associated with Reduced Kidney Function in a Chinese Han Population. <i>Kidney and Blood Pressure Research</i> , 2017, 42, 43-51.	0.9	3
335	Urea-induced ROS accelerate senescence in endothelial progenitor cells. <i>Atherosclerosis</i> , 2017, 263, 127-136.	0.4	26
336	Exploring binding characteristics and the related competition of different protein-bound uremic toxins. <i>Biochimie</i> , 2017, 139, 20-26.	1.3	19
337	Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. <i>Nature Reviews Nephrology</i> , 2017, 13, 393-409.	4.1	200
338	ApoB and apoM "New aspects of lipoprotein biology in uremia-induced atherosclerosis. <i>European Journal of Pharmacology</i> , 2017, 816, 154-160.	1.7	8
339	Markers of endothelial damage in patients with chronic kidney disease on hemodialysis. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 312, F673-F681.	1.3	33
340	Fibroblast Growth Factor-23: A Novel Biomarker for Cardiovascular Disease in Chronic Kidney Disease Patients. <i>Prilozi - Makedonska Akademija Na Naukite I Umetnostite Oddelenie Za Medicinski Nauki</i> , 2017, 38, 19-27.	0.2	4
341	Uremia does not affect neointima formation in mice. <i>Scientific Reports</i> , 2017, 7, 6496.	1.6	4

#	ARTICLE	IF	CITATIONS
342	Impact of extended ginsenoside Rb1 on early chronic kidney disease: a randomized, placebo-controlled study. <i>Inflammopharmacology</i> , 2017, 25, 33-40.	1.9	33
343	NETosis provides the link between activation of neutrophils on hemodialysis membrane and comorbidities in dialyzed patients. <i>Inflammation Research</i> , 2017, 66, 369-378.	1.6	23
344	p-Cresyl Sulfate. <i>Toxins</i> , 2017, 9, 52.	1.5	262
345	Uremic Toxin Section in the Journal <i>Toxins</i> : A Powerful Tool to Bundle and Advance Knowledge on Uremia. <i>Toxins</i> , 2017, 9, 170.	1.5	1
346	Skin- and Plasmaautofluorescence in hemodialysis with glucose-free or glucose-containing dialysate. <i>BMC Nephrology</i> , 2017, 18, 5.	0.8	7
347	Ankle-brachial Index for the Prognosis of Cardiovascular Disease in Patients with Mild Renal Insufficiency. <i>Internal Medicine</i> , 2017, 56, 2103-2111.	0.3	8
348	Aryl hydrocarbon receptor is activated in patients and mice with chronic kidney disease. <i>Kidney International</i> , 2018, 93, 986-999.	2.6	79
349	Expanded Haemodialysis Therapy of Chronic Haemodialysis Patients Prevents Calcification and Apoptosis of Vascular Smooth Muscle Cells in vitro. <i>Blood Purification</i> , 2018, 45, 131-138.	0.9	20
350	Urea and chronic kidney disease: the comeback of the century? (in uraemia research). <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 4-12.	0.4	122
351	Mortality prediction in stable hemodialysis patients is refined by YKL-40, a 40-kDa glycoprotein associated with inflammation. <i>Kidney International</i> , 2018, 93, 221-230.	2.6	25
352	Incident CKD after Radical or Partial Nephrectomy. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 207-216.	3.0	55
353	Precise Quantitative Assessment of the Clinical Performances of Two High-Flux Polysulfone Hemodialyzers in Hemodialysis: Validation of a Blood-Based Simple Kinetic Model Versus Direct Dialysis Quantification. <i>Artificial Organs</i> , 2018, 42, E55-E66.	1.0	8
354	Arterial stiffness in black African ancestry patients with chronic kidney disease living in Cameroon. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 450-459.	0.7	1
355	Introduction to the <i>Toxins</i> Special Issue on "Novel Issues in Uremic Toxicity". <i>Toxins</i> , 2018, 10, 388.	1.5	5
356	Oxidative stress in chronic kidney disease. <i>Renal Replacement Therapy</i> , 2018, 4, .	0.3	82
357	The Number of Comorbidities Predicts Renal Outcomes in Patients with Stage 3-5 Chronic Kidney Disease. <i>Journal of Clinical Medicine</i> , 2018, 7, 493.	1.0	77
358	Glomerular filtration rate: A prognostic marker in atrial fibrillation? A subanalysis of the AntiThrombotic Agents Atrial Fibrillation. <i>Clinical Cardiology</i> , 2018, 41, 1570-1577.	0.7	8
359	Lipid management in patients with chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2018, 14, 727-749.	4.1	153

#	ARTICLE	IF	CITATIONS
360	The uremic solute-AHR-tissue factor axis in vascular cells, mouse models and thrombosis in chronic kidney disease patients. <i>Annals of Translational Medicine</i> , 2018, 6, 225-225.	0.7	2
361	Urea Memory: Transient Cell Exposure to Urea Causes Persistent Mitochondrial ROS Production and Endothelial Dysfunction. <i>Toxins</i> , 2018, 10, 410.	1.5	12
362	Management of Hypertension in Renal Disease in Pregnancy. , 0, , 87-100.		0
363	Dietary Changes Involving <i>Lactobacillus Bifidobacterium</i> and <i>Lactobacillus longum</i> and Other Nutrients Delays Chronic Kidney Disease Progression. <i>American Journal of Nephrology</i> , 2018, 47, 325-332.	1.4	30
364	Developmental Programming of Renal Function and Re-Programming Approaches. <i>Frontiers in Pediatrics</i> , 2018, 6, 36.	0.9	25
365	Left ventricular hypertrophy predicts the decline of glomerular filtration rate in patients with type 2 diabetes mellitus. <i>International Urology and Nephrology</i> , 2018, 50, 2049-2059.	0.6	5
366	Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD). <i>Toxins</i> , 2018, 10, 237.	1.5	28
367	Assessment of the association between increasing membrane pore size and endotoxin permeability using a novel experimental dialysis simulation set-up. <i>BMC Nephrology</i> , 2018, 19, 1.	0.8	91
368	Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University. <i>Clinical Research in Cardiology</i> , 2018, 107, 120-126.	1.5	25
369	Urinary peptide biomarker panel associated with an improvement in estimated glomerular filtration rate in chronic kidney disease patients. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 751-759.	0.4	15
370	Oxidative stress in chronic kidney disease. <i>Pediatric Nephrology</i> , 2019, 34, 975-991.	0.9	483
371	Contribution of the uremic milieu to an increased pro-inflammatory monocytic phenotype in chronic kidney disease. <i>Scientific Reports</i> , 2019, 9, 10236.	1.6	21
372	Low Birth Weight and Kidney Function in Middle-Aged Men and Women: The Netherlands Epidemiology of Obesity Study. <i>American Journal of Kidney Diseases</i> , 2019, 74, 751-760.	2.1	12
373	A Portable Color Sensor Based Urine Analysis System to Detect Chronic Kidney Disease. , 2019, , .		4
374	The relationship between estimated glomerular filtration rate and urine m/creatinine ratio and parathyroid hormone in elderly Koreans. <i>Hormones</i> , 2019, 18, 485-494.	0.9	0
375	An in-vitro assay using human spermatozoa to detect toxicity of biologically active substances. <i>Scientific Reports</i> , 2019, 9, 14525.	1.6	5
376	High urea induces depression and LTP impairment through mTOR signalling suppression caused by carbamylation. <i>EBioMedicine</i> , 2019, 48, 478-490.	2.7	28
377	Long-term effect of medium cut-off dialyzer on middle uremic toxins and cell-free hemoglobin. <i>PLoS ONE</i> , 2019, 14, e0220448.	1.1	29

#	ARTICLE	IF	CITATIONS
378	Respiratory sympathetic modulation is augmented in chronic kidney disease. <i>Respiratory Physiology and Neurobiology</i> , 2019, 262, 57-66.	0.7	5
379	miR-223 and other miRNA's evaluation in chronic kidney disease: Innovative biomarkers and therapeutic tools. <i>Non-coding RNA Research</i> , 2019, 4, 30-35.	2.4	28
380	Dysfunctional high-density lipoprotein activates toll-like receptors via serum amyloid A in vascular smooth muscle cells. <i>Scientific Reports</i> , 2019, 9, 3421.	1.6	22
381	Prescribing Trend of Antirheumatic Drugs in Taiwan and Risk of Cardiovascular Disease in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study. <i>BioMed Research International</i> , 2019, 2019, 1-8.	0.9	5
382	Review of the efficacy of AST-120 (KREMEZIN [®]) on renal function in chronic kidney disease patients. <i>Renal Failure</i> , 2019, 41, 47-56.	0.8	59
383	Renal Disease is Associated with Poor Outcomes Following Isolated Coronary Artery Bypass Grafting. <i>Global Heart</i> , 2019, 14, 347.	0.9	3
384	Renal impairment after ileostomy formation: a frequent event with long-term consequences. <i>Colorectal Disease</i> , 2020, 22, 269-278.	0.7	49
385	The Uremic Syndrome. , 2020, , 199-210.		1
386	Impaired Delivery of Cholesterol Effluxed From Macrophages to Hepatocytes by Serum From CKD Patients May Underlie Increased Cardiovascular Disease Risk. <i>Kidney International Reports</i> , 2020, 5, 199-210.	0.4	7
387	Spinal Cord Ischemia in Pancreas Transplantation: The UK Experience. <i>Transplantation</i> , 2020, 104, 1959-1965.	0.5	7
388	Indoxyl sulfate and high-density lipoprotein cholesterol in early stages of chronic kidney disease. <i>Renal Failure</i> , 2020, 42, 1157-1163.	0.8	3
389	Encapsulation of Activated Carbon into a Hollow-Type Spherical Bacterial Cellulose Gel and Its Indole-Adsorption Ability Aimed at Kidney Failure Treatment. <i>Pharmaceutics</i> , 2020, 12, 1076.	2.0	5
390	Receptor for Advanced Glycation End Products is Involved in Platelet Hyperactivation and Arterial Thrombosis during Chronic Kidney Disease. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1300-1312.	1.8	5
391	Amino Acid Metabolites Associated with Chronic Kidney Disease: An Eight-Year Follow-Up Korean Epidemiology Study. <i>Biomedicines</i> , 2020, 8, 222.	1.4	40
392	Endocan: A novel biomarker for risk stratification, prognosis and therapeutic monitoring in human cardiovascular and renal diseases. <i>Clinica Chimica Acta</i> , 2020, 509, 310-335.	0.5	21
393	Chronic Kidney Disease as Oxidative Stress- and Inflammatory-Mediated Cardiovascular Disease. <i>Antioxidants</i> , 2020, 9, 752.	2.2	133
394	Prevalence and health correlates of reduced kidney function among community-dwelling Chinese older adults: the China Health and Retirement Longitudinal Study. <i>BMJ Open</i> , 2020, 10, e042396.	0.8	3
395	Uremic Apelin and Leucocytic Angiotensin-Converting Enzyme 2 in CKD Patients. <i>Toxins</i> , 2020, 12, 742.	1.5	1

#	ARTICLE	IF	CITATIONS
396	Current Therapy in CKD Patients Can Affect Vitamin K Status. <i>Nutrients</i> , 2020, 12, 1609.	1.7	11
397	CKD Increases Carbonylation of HDL and Is Associated with Impaired Antiaggregant Properties. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1462-1477.	3.0	14
398	Exacerbation of Hyperparathyroidism, Secondary to a Reduction in Kidney Function, in Individuals With Vitamin D Deficiency. <i>Frontiers in Medicine</i> , 2020, 7, 221.	1.2	3
399	Editorial on the Special Issue "Comorbidities in Chronic Kidney Disease". <i>Toxins</i> , 2020, 12, 384.	1.5	4
400	CharXgen-Activated Bamboo Charcoal Encapsulated in Sodium Alginate Microsphere as the Absorbent of Uremic Toxins to Retard Kidney Function Deterioration. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1257.	1.8	4
401	Behavioral Changes During Development of Chronic Kidney Disease in Rats. <i>Frontiers in Medicine</i> , 2019, 6, 311.	1.2	15
402	Role of S-Equol, Indoxyl Sulfate, and Trimethylamine N-Oxide on Vascular Function. <i>American Journal of Hypertension</i> , 2020, 33, 793-803.	1.0	21
403	Mechanisms of Cardiovascular Disorders in Patients With Chronic Kidney Disease: A Process Related to Accelerated Senescence. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 185.	1.8	76
404	Medium cut-off dialyzers in a large population of hemodialysis patients in Colombia: COREXH registry. <i>Therapeutic Apheresis and Dialysis</i> , 2021, 25, 33-43.	0.4	18
405	Physical activity for patients with CKD. , 2021, , 117-139.		0
406	The effects of twenty-four nutrients and phytonutrients on immune system function and inflammation: a narrative review. <i>Journal of Clinical and Translational Research</i> , 0, , .	0.3	9
407	Protein-Bound Uremic Toxins Quantification by a Colorimetric Sensor Based on the Oxidation of Silver Nanoparticles. <i>IEEE Sensors Journal</i> , 2021, 21, 22651-22660.	2.4	1
408	In vitro anti-inflammatory effects of vitamin D supplementation may be blurred in hemodialysis patients. <i>Clinics</i> , 2021, 76, e1821.	0.6	5
409	A history of uremic toxicity and of the European Uremic Toxin Work Group (EUTox). <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1514-1523.	1.4	8
410	PHYSIOLOGICAL AND HISTOLOGICAL STUDIES OF THE EFFECT OF SILDENAFIL ON ADENINE-INDUCED NEPHROTOXICITY IN THE SPRAGUE-DAWLEY RAT. <i>Plant Archives</i> , 2021, 21, 1074-1078.	0.1	0
411	EDTAKI: a Nephrology and Public Policy Committee platform call for more European involvement in acute kidney injury. <i>Nephrology Dialysis Transplantation</i> , 2021, , .	0.4	4
412	Medium Cut-Off Dialysis Membrane and Dietary Fiber Effects on Inflammation and Protein-Bound Uremic Toxins: A Systematic Review and Protocol for an Interventional Study. <i>Toxins</i> , 2021, 13, 244.	1.5	5
413	Thrombolome and Its Emerging Role in Chronic Kidney Diseases. <i>Toxins</i> , 2021, 13, 223.	1.5	11

#	ARTICLE	IF	CITATIONS
414	<sc>TWEAK</sc> as a common pathway in the heart and the kidneys in cardiorenal syndrome. <i>Journal of Pathology</i> , 2021, 254, 5-19.	2.1	7
415	Fighting the unbearable lightness of neglecting kidney health: the decade of the kidney. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1719-1730.	1.4	41
416	Uremic Toxins and Their Relation with Oxidative Stress Induced in Patients with CKD. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6196.	1.8	30
417	Effects of intradialytic progressive resistance training on muscle strength, physical capacity and quality of life in end-stage renal disease patients. <i>Research, Society and Development</i> , 2021, 10, e33710918195.	0.0	0
418	The Relationship Between Carotid Intima Media Thickness, Inflammation and GLA Rich Protein Levels in Chronic Kidney Disease. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5119-5126.	0.8	1
419	Association between neighborhood social cohesion, awareness of chronic diseases, and participation in healthy behaviors in a community cohort. <i>BMC Public Health</i> , 2021, 21, 1611.	1.2	19
420	Coronary artery calcification progression and long-term cardiovascular outcomes in renal transplant recipients: an analysis by the joint model. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 101-108.	1.4	2
421	Biomarkers of Uremic Cardiotoxicity. <i>Toxins</i> , 2021, 13, 639.	1.5	2
422	Cardiovascular Disease and Inflammation. , 2021, , 1-22.		0
423	The relationship between calcification inhibitor levels in chronic kidney disease and the development of atherosclerosis. <i>Renal Failure</i> , 2021, 43, 1349-1358.	0.8	11
424	Inhibition of vascular calcification by inositol phosphates derivatized with ethylene glycol oligomers. <i>Nature Communications</i> , 2020, 11, 721.	5.8	38
425	In Vitro Dialysis of Cytokine-Rich Plasma With High and Medium Cut-Off Membranes Reduces Its Procalcific Activity. <i>Artificial Organs</i> , 2017, 41, 803-809.	1.0	11
426	Risk Factors for Cardiovascular Disease in Patients Undergoing Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2007, 27, 205-209.	1.1	52
427	Elimination of Endogenous Toxin, Creatinine from Blood Plasma Depends on Albumin Conformation: Site Specific Uremic Toxicity & Impaired Drug Binding. <i>PLoS ONE</i> , 2011, 6, e17230.	1.1	108
428	Determinants of Arterial Stiffness in Chronic Kidney Disease Stage 3. <i>PLoS ONE</i> , 2013, 8, e55444.	1.1	36
429	Uremic Conditions Drive Human Monocytes to Pro-Atherogenic Differentiation via an Angiotensin-Dependent Mechanism. <i>PLoS ONE</i> , 2014, 9, e102137.	1.1	20
430	Transcriptome Analysis in Patients with Chronic Kidney Disease on Hemodialysis Disclosing a Key Role for CD16+CX3CR1+ Monocytes. <i>PLoS ONE</i> , 2015, 10, e0121750.	1.1	13
431	Meta-Analysis of the Associations of p-Cresyl Sulfate (PCS) and Indoxyl Sulfate (IS) with Cardiovascular Events and All-Cause Mortality in Patients with Chronic Renal Failure. <i>PLoS ONE</i> , 2015, 10, e0132589.	1.1	182

#	ARTICLE	IF	CITATIONS
432	Angiotensin-2 as a Prognostic Biomarker of Major Adverse Cardiovascular Events and All-Cause Mortality in Chronic Kidney Disease. PLoS ONE, 2015, 10, e0135181.	1.1	24
433	Using controlled attenuation parameter combined with ultrasound to survey non-alcoholic fatty liver disease in hemodialysis patients: A prospective cohort study. PLoS ONE, 2017, 12, e0176027.	1.1	11
434	Ingreso a diálisis y mortalidad en un programa de prevención de la enfermedad renal crónica en Colombia. Revista Facultad De Medicina, 2015, 63, 209-216.	0.0	5
435	Transmission of SARS-CoV-2 Involving Residents Receiving Dialysis in a Nursing Home " Maryland, April 2020. Morbidity and Mortality Weekly Report, 2020, 69, 1089-1094.	9.0	21
436	Co-morbidade e mortalidade de pacientes em início de diálise. ACTA Paulista De Enfermagem, 2006, 19, 304-309.	0.1	18
437	Increased Levels of Total P-Cresylsulphate and Indoxyl Sul-phate are Associated with Coronary Artery Disease in Patients with Diabetic Nephropathy. Review of Diabetic Studies, 2010, 7, 275-284.	0.5	64
438	Routine iso-osmolar contrast media use and acute kidney injury following percutaneous coronary intervention for ST elevation myocardial infarction. Minerva Cardioangiologica, 2019, 67, 380-391.	1.2	4
439	Prevalence and Consequences of Nonadherence to Hemodialysis Regimens. American Journal of Critical Care, 2007, 16, 222-235.	0.8	209
440	A prospective study of pulmonary hypertension in patients with chronic kidney disease: A new and pernicious complication. Indian Journal of Nephrology, 2017, 28, 127-134.	0.2	11
441	Evaluation of left ventricular mechanical dyssynchrony with phase analysis in end-stage renal disease patients with normal gated SPECT-MPI. World Journal of Nuclear Medicine, 2019, 18, 238-243.	0.3	2
442	Vascular toxicity of urea, a new "old player" in the pathogenesis of chronic renal failure induced cardiovascular diseases. Turk Pediatri Arsivi, 2018, 52, 187-193.	0.9	6
443	Associations among chronic kidney disease, high total p-cresylsulfate and major adverse cardiac events. Journal of Nephrology, 2013, 26, 111-118.	0.9	25
444	Hypertension in Renal Failure. , 2007, , 693-705.		0
446	Cardiovascular Disease and Inflammation. , 2009, , 679-695.		0
447	Role of Neurohormonal Activation in the Pathogenesis of Cardiovascular Complications in Chronic Kidney Disease. , 2010, , 279-290.		0
448	Cardiovascular Complications in Renal Failure: Implications of Advanced Glycation End Products and Their Receptor RAGE. , 2011, , 257-292.		0
449	Comparison of Hospitalization and Survival Between Patients Treated With Renal Replacement Therapy. Turkish Nephrology, Dialysis and Transplantation Journal, 2011, 20, 72-76.	0.0	0
450	Prognostic implications of plasma myoglobin levels in patients with chronic kidney disease. International Journal of Artificial Organs, 2012, 35, 959-968.	0.7	5

#	ARTICLE	IF	CITATIONS
451	The Association Between Progression of Carotid Artery Intima-Media Thickness and Cardiovascular Events in Peritoneal Dialysis Patients. Turkish Nephrology, Dialysis and Transplantation Journal, 2013, 22, 238-244.	0.0	0
452	Cardiorenal syndrome in patients with chronic kidney disease and diabetes mellitus. Diabetes Mellitus, 2013, 16, 90-96.	0.5	2
453	Cardiovascular Disease in Pediatric Chronic Kidney Disease. Journal of the Korean Society of Pediatric Nephrology, 2014, 18, 7.	0.1	0
455	ANAESTHESIA FOR CHRONIC RENAL DISEASE AND RENAL TRANSPLANT: AN UPDATE. Journal of Evolution of Medical and Dental Sciences, 2015, 04, 3346-3364.	0.1	2
456	The Relationship Between Osteoprotegerin/RANKL Axis and Arterial Stiffness in Osteopenic/Osteoporotic Renal Transplantation Recipients. Turkish Nephrology, Dialysis and Transplantation Journal, 2015, 24, 181-188.	0.0	0
457	Anesthetic Experience of 1000 Cases During 10 Years in Renal Transplantation: A Retrospective Study. Thrita, 2015, 4, .	0.4	0
458	Is there any Gender Difference in the Association between Obesity, Chronic Kidney Disease and Anemia. BANTAO Journal, 2015, 13, 79-83.	0.1	0
459	Chronische Nierenerkrankungen im Erwachsenenalter. , 2016, , 373-382.		0
460	Anaesthesia and intensive care for simultaneous liver-kidney transplantation: A single-centre experience with 12 recipients. Indian Journal of Anaesthesia, 2016, 60, 476.	0.3	3
461	Factors that Influence Graft Function at 1-Year Posttransplantation and Correlation with Baseline Donated Kidney Function Measured with Radioisotopes. BANTAO Journal, 2016, 14, 23-29.	0.1	0
464	Chronic Kidney Disease is a Common Medical Problem. Ukrainian Journal of Medicine and Sports, 2018, 3, 185-193.	0.0	0
465	Does Vitamin K Intake Influence High Phosphate Induced Vascular Pseudo-ossification: An Underappreciated Therapeutic Prospect in General Population?. Current Drug Targets, 2019, 20, 421-430.	1.0	0
466	A pilot study to assess kidney functions and toxic dimethyl-arginines as risk biomarkers in women with low vitamin D levels. Journal of Medical Biochemistry, 2019, 38, 145-152.	0.7	7
467	Ergocalciferol improves endothelial vasodilatory and vasoconstrictor function in an <i>in vivo</i> model of mild uraemia. Bioscience Reports, 2019, 39, .	1.1	2
468	The renal patient seen by non-renal physicians: the kidney embedded in the "milieu intérieur". CKJ: Clinical Kidney Journal, 2021, 14, 1077-1087.	1.4	1
469	Calcium, phosphate, PTH, vitamin D, and FGF-23 in CKD-mineral and bone disorder. , 2022, , 353-381.		2
470	Cardiovascular Disease Burden in Patients with Non-Dialysis Dependent Chronic Kidney Disease in Cameroon: Case of the Douala General Hospital. Open Journal of Nephrology, 2020, 10, 171-186.	0.0	0
471	COMPARATIVE METABOLOMIC STUDY OF HIGH-FLUX HEMODIALYSIS AND HIGH VOLUME ONLINE HEMODIAFILTRATION IN THE REMOVAL OF UREMIC TOXINS USING 1H NMR SPECTROSCOPY. Journal of Pharmaceutical and Biomedical Analysis, 2021, 208, 114460.	1.4	2

#	ARTICLE	IF	CITATIONS
472	The Relationship between the Progression of Chronic Kidney Disease and Beta Cell Function in Non-Diabetic Korean Adults. <i>Korean Journal of Clinical Laboratory Science</i> , 2020, 52, 165-171.	0.1	2
473	Anaesthesia for renal transplantation: an update. <i>Indian Journal of Anaesthesia</i> , 2009, 53, 139-47.	0.3	17
474	Increased risk of mortality among haemodialysis patients with or without prior stroke: a nationwide population-based study in Taiwan. <i>Indian Journal of Medical Research</i> , 2013, 138, 232-8.	0.4	2
475	Protein-bound P-cresol inhibits human umbilical vein endothelial cell proliferation by inducing cell cycle arrest at G/G. <i>American Journal of Translational Research (discontinued)</i> , 2017, 9, 2013-2023.	0.0	6
476	The effects of twenty-four nutrients and phytonutrients on immune system function and inflammation: A narrative review. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 333-376.	0.3	6
477	Ɖardiorenal Syndrome in Patients on Renal Replacement Therapy. , 0, , .		0
478	The prognostic role of heart rate recovery after exercise and metabolic syndrome in IgA nephropathy. <i>BMC Nephrology</i> , 2021, 22, 390.	0.8	3
479	Computational Identification and 3D Morphological Characterization of Renal Glomeruli in Optically Cleared Murine Kidneys. <i>Sensors</i> , 2021, 21, 7440.	2.1	2
480	Mineralocorticoid receptor antagonists for cardioprotection in chronic kidney disease: a step into the future. <i>Journal of Human Hypertension</i> , 2022, 36, 695-704.	1.0	2
481	Predictors of Late Mortality in Patients With Surgically Resected Cardiac Myxomas: A Single-Center Experience. <i>Cureus</i> , 2022, 14, e20866.	0.2	1
482	Predicting 3-month and 1-year mortality for patients initiating dialysis: a population-based cohort study. <i>Journal of Nephrology</i> , 2022, , 1.	0.9	1
483	Kidney Function According to Different Equations in Patients Admitted to a Cardiology Unit and Impact on Outcome. <i>Journal of Clinical Medicine</i> , 2022, 11, 891.	1.0	5
484	Urea levels and cardiovascular disease in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 184-192.	0.4	9
485	Association between retinal vein occlusion and Lifeâ€™s Simple 7 cardiovascular health metrics: A large claims database study. <i>Ophthalmology Retina</i> , 2022, , .	1.2	2
486	Indoxyl sulfate- and P-cresol-induced monocyte adhesion and migration is mediated by integrin-linked kinase-dependent podosome formation. <i>Experimental and Molecular Medicine</i> , 2022, 54, 226-238.	3.2	8
487	Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently. <i>Diabetes Therapy</i> , 2022, 13, 889-911.	1.2	2
488	Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study. <i>Diabetes and Metabolism</i> , 2022, 48, 101344.	1.4	15
489	New Therapeutic Horizons in Chronicâ€™Kidneyâ€™Disease: The Role of SGLT2 Inhibitors in Clinical Practice. <i>Drugs</i> , 2022, 82, 97-108.	4.9	4

#	ARTICLE	IF	CITATIONS
490	Renal Function Mediates the Association Between Klotho and Congestive Heart Failure Among Middle-Aged and Older Individuals. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 802287.	1.1	2
491	Exercise reduces the risk of chronic kidney disease in individuals with nonalcoholic fatty liver disease: A nationwide cohort study. <i>Diabetes and Metabolism</i> , 2022, 48, 101362.	1.4	3
492	Reliability and validity of a new baseline renal function calculator after radical nephrectomy in a Malaysian population. <i>Urological Science</i> , 2022, 33, 82.	0.2	0
493	Severe Coronary Problems in Kidney Illness: Medical and Therapeutic Features. <i>Pakistan Biomedical Journal</i> , 0, , 125-129.	0.0	0
494	The European Kidney Health Alliance (EKHA) and the Decade of the Kidney™. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 1113-1122.	0.4	7
496	Uremic Toxicity. , 2023, , 16-44.		1
497	Protein/Fiber Index Modulates Uremic Toxin Concentrations in Hemodialysis Patients. <i>Toxins</i> , 2022, 14, 589.	1.5	4
498	Brassica oleracea L. var. botrytis Leaf Extract Alleviates Gentamicin-Induced Hepatorenal Injury in Rats—Possible Modulation of IL-1 β and NF- κ B Activity Assisted with Computational Approach. <i>Life</i> , 2022, 12, 1370.	1.1	3
499	Chronic Kidney Disease in Balkan Countries—A Call to Action for Timely Diagnosis and Monitoring. <i>Diagnostics</i> , 2022, 12, 2162.	1.3	0
500	Renal fat fraction is significantly associated with the risk of chronic kidney disease in patients with type 2 diabetes. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	3
501	Trimethylamine, a gut bacteria metabolite and air pollutant, increases blood pressure and markers of kidney damage including proteinuria and KIM-1 in rats. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	11
502	Gut microbiome studies in CKD: opportunities, pitfalls and therapeutic potential. <i>Nature Reviews Nephrology</i> , 2023, 19, 87-101.	4.1	19
503	Utilizing Rayleigh light scattering of anthracene nanoparticles for determination of p-cresol in exhaled breath condensate. <i>Microchemical Journal</i> , 2023, 187, 108387.	2.3	1
504	Cardiovascular Disease and Inflammation. , 2023, , 575-596.		1
506	Chronic kidney disease and severe mental illness: a scoping review. <i>Journal of Nephrology</i> , 2023, 36, 1519-1547.	0.9	4
507	Multifactorial glial responses and their contributions to Alzheimer's disease continuum. <i>Clinical and Experimental Neuroimmunology</i> , 2023, 14, 82-91.	0.5	1
508	Impact of anemia treatment for left ventricular hypertrophy using long-acting erythropoietin-stimulating agents from the pre-dialysis to maintenance dialysis period in patients with chronic kidney disease, retrospective longitudinal cohort study. <i>BMC Nephrology</i> , 2023, 24, .	0.8	0
509	Risk Assessment of Pre-dialysis Chronic Kidney Disease (CKD) Patients for Cardiovascular Disease (CVD) in a Tertiary Hospital in Nigeria: A Case-Controlled Cross-Sectional Study. <i>Cureus</i> , 2023, , .	0.2	1

#	ARTICLE	IF	CITATIONS
510	Cardiovascular diseases morbidity and mortality among children, adolescents and young adults with dialysis therapy. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	0
511	Role of the Microbiome in Gut-Heart-Kidney Cross Talk. <i>Circulation Research</i> , 2023, 132, 1064-1083.	2.0	12